Unity Biotechnology (NASDAQ:UBX) Trading Down 1.8%

Unity Biotechnology, Inc. (NASDAQ:UBX)’s stock price was down 1.8% during trading on Thursday . The stock traded as low as $1.56 and last traded at $1.60. Approximately 15,774 shares were traded during trading, a decline of 80% from the average daily volume of 79,477 shares. The stock had previously closed at $1.63.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their target price on shares of Unity Biotechnology from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, April 16th.

Unity Biotechnology Stock Down 1.8 %

The company has a fifty day simple moving average of $1.57 and a 200 day simple moving average of $1.74. The firm has a market capitalization of $26.86 million, a P/E ratio of -0.54 and a beta of 0.86.

Unity Biotechnology (NASDAQ:UBX) last announced its quarterly earnings data on Monday, April 15th. The company reported ($0.53) EPS for the quarter. As a group, equities analysts expect that Unity Biotechnology, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Trading of Unity Biotechnology

A hedge fund recently bought a new stake in Unity Biotechnology stock. Armistice Capital LLC purchased a new stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 688,000 shares of the company’s stock, valued at approximately $1,328,000. Armistice Capital LLC owned approximately 4.10% of Unity Biotechnology at the end of the most recent reporting period. Institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.